# Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

> **NCT01299545** · — · TERMINATED · sponsor: **TcLand Expression S.A.** · enrollment: 123 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01299545
- **Lead sponsor:** TcLand Expression S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 123 (ACTUAL)
- **Why stopped:** Recruitment difficulties
- **Last updated:** 2013-02-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01299545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01299545, "Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01299545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*